share_log

EyePoint Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Zaderej Karen L.

SEC ·  Jul 13 05:04
Summary by Futu AI
On July 11, 2024, Karen L. Zaderej, associated with EyePoint Pharmaceuticals, Inc. (EYPT), completed a transaction to acquire 2,000 shares of the company's common stock at no cost. This transaction was categorized as an exercise or conversion of derivative security, which is typically related to options or warrants being converted into stock. Following this acquisition, Zaderej's direct holdings in EyePoint Pharmaceuticals increased to a total of 4,000 shares of common stock.
On July 11, 2024, Karen L. Zaderej, associated with EyePoint Pharmaceuticals, Inc. (EYPT), completed a transaction to acquire 2,000 shares of the company's common stock at no cost. This transaction was categorized as an exercise or conversion of derivative security, which is typically related to options or warrants being converted into stock. Following this acquisition, Zaderej's direct holdings in EyePoint Pharmaceuticals increased to a total of 4,000 shares of common stock.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated